Biotech Co. To Face Amended Investor Suit Over COVID Test

By Sydney Price · May 1, 2023, 6:25 PM EDT

A California federal judge has declined to dismiss an amended investor complaint against a biotech company over issues with its COVID-19 test rollout, holding the revised suit plausibly alleges the defendants...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

IN RE Talis Biomedical Securities Litigation

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 07, 2022

Recent Articles By Sydney

July 10, 2024
Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud
July 08, 2024
UnitedHealth Brass Face Investor Suit Over Merger Probe
July 08, 2024
Medical Device Co. SeaStar Sued Over Regulatory Disclosures
July 02, 2024
Pharma Co. Scores Exit In Investor Suit Over Primate Imports
June 06, 2024
Pharma Co. Misled Investors On Seizure Drug Trial, Suit Says
May 15, 2024
UnitedHealth Concealed DOJ Merger Investigation, Suit Says
May 13, 2024
Biogen Investors Seek Class Cert. In Alzheimer's Drug Suit
May 08, 2024
Shockwave Medical Investor Challenges $13B Deal With J&J
May 07, 2024
Pharma Co. Falsely Touted Obesity Drug Results, Suit Claims
May 06, 2024
Judge Trims ESOP Valuation Suit Against Healthcare Co.